Cargando…
Development and Validation of the Korean Version of Expanded Prostate Cancer Index Composite: Questionnaire Assessing Health-Related Quality of Life after Prostate Cancer Treatment
PURPOSE: Although the quality of life (QoL) of prostate cancer (PCa) patients is a major issue, there is no unified and useful methodology for assessing QoL. The Expanded Prostate Cancer Index Composite (EPIC) is a globally used tool to measure QoL after PCa treatment that comprises urinary, bowel,...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Korean Urological Association
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941808/ https://www.ncbi.nlm.nih.gov/pubmed/20856644 http://dx.doi.org/10.4111/kju.2010.51.9.601 |
_version_ | 1782186940112568320 |
---|---|
author | Chung, Kyung Jin Kim, Jung Jun Lim, Soo Hyun Kim, Tae Heon Han, Deok Hyun Lee, Sung Won |
author_facet | Chung, Kyung Jin Kim, Jung Jun Lim, Soo Hyun Kim, Tae Heon Han, Deok Hyun Lee, Sung Won |
author_sort | Chung, Kyung Jin |
collection | PubMed |
description | PURPOSE: Although the quality of life (QoL) of prostate cancer (PCa) patients is a major issue, there is no unified and useful methodology for assessing QoL. The Expanded Prostate Cancer Index Composite (EPIC) is a globally used tool to measure QoL after PCa treatment that comprises urinary, bowel, sexual, and hormonal domains. Acknowledging the need for such a tool applicable to Korean PCa patients, we translated EPIC into Korean and validated the new version. MATERIALS AND METHODS: The Korean version of EPIC was devised by translation, back-translation, and reconciliation. Subsequently, we randomly selected 153 patients with localized PCa treated with radical perineal prostatectomy (67, 43.8%), radical retropubic prostatectomy (19, 12.4%), laparoscopic radical prostatectomy (12, 7.8%), robot-assisted laparoscopic radical prostatectomy (36, 23.5%), and high-intensity focused ultrasound ablation of the prostate (19, 12.4%) and asked them to complete EPIC. Reliability was assessed by test-retest correlation and Cronbach's alpha. Validity was assessed by factor analysis, interscale correlation, and correlation with Functional Assessment of Cancer Therapy-Prostate (FACT-P). RESULTS: Test-retest correlation and Cronbach's alpha were high in each of the domains (0.92, 0.91, 0.76, 0.84 and 0.86, 0.84, 0.92, 0.83, p<0.0001). Interscale correlation among the domains was low (r<0.37), which indicated that EPIC is composed of proper domains. Interscale correlation between the function and bother subscales was high (0.94, 0.81, 0.84 and 0.80, p<0.0001). EPIC domains had low correlation with FACT-P, permitting complementary use. CONCLUSIONS: The Korean version of EPIC was developed by a proper process, as evident by its high reliability and validity. Therefore, it is a reliable, comprehensive, systematic method that evaluates QoL in Korean patients after PCa treatment. Furthermore, it can be adapted as an objective methodology for research globally. |
format | Text |
id | pubmed-2941808 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | The Korean Urological Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-29418082010-09-20 Development and Validation of the Korean Version of Expanded Prostate Cancer Index Composite: Questionnaire Assessing Health-Related Quality of Life after Prostate Cancer Treatment Chung, Kyung Jin Kim, Jung Jun Lim, Soo Hyun Kim, Tae Heon Han, Deok Hyun Lee, Sung Won Korean J Urol Original Article PURPOSE: Although the quality of life (QoL) of prostate cancer (PCa) patients is a major issue, there is no unified and useful methodology for assessing QoL. The Expanded Prostate Cancer Index Composite (EPIC) is a globally used tool to measure QoL after PCa treatment that comprises urinary, bowel, sexual, and hormonal domains. Acknowledging the need for such a tool applicable to Korean PCa patients, we translated EPIC into Korean and validated the new version. MATERIALS AND METHODS: The Korean version of EPIC was devised by translation, back-translation, and reconciliation. Subsequently, we randomly selected 153 patients with localized PCa treated with radical perineal prostatectomy (67, 43.8%), radical retropubic prostatectomy (19, 12.4%), laparoscopic radical prostatectomy (12, 7.8%), robot-assisted laparoscopic radical prostatectomy (36, 23.5%), and high-intensity focused ultrasound ablation of the prostate (19, 12.4%) and asked them to complete EPIC. Reliability was assessed by test-retest correlation and Cronbach's alpha. Validity was assessed by factor analysis, interscale correlation, and correlation with Functional Assessment of Cancer Therapy-Prostate (FACT-P). RESULTS: Test-retest correlation and Cronbach's alpha were high in each of the domains (0.92, 0.91, 0.76, 0.84 and 0.86, 0.84, 0.92, 0.83, p<0.0001). Interscale correlation among the domains was low (r<0.37), which indicated that EPIC is composed of proper domains. Interscale correlation between the function and bother subscales was high (0.94, 0.81, 0.84 and 0.80, p<0.0001). EPIC domains had low correlation with FACT-P, permitting complementary use. CONCLUSIONS: The Korean version of EPIC was developed by a proper process, as evident by its high reliability and validity. Therefore, it is a reliable, comprehensive, systematic method that evaluates QoL in Korean patients after PCa treatment. Furthermore, it can be adapted as an objective methodology for research globally. The Korean Urological Association 2010-09 2010-09-16 /pmc/articles/PMC2941808/ /pubmed/20856644 http://dx.doi.org/10.4111/kju.2010.51.9.601 Text en Copyright © The Korean Urological Association, 2010 http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Chung, Kyung Jin Kim, Jung Jun Lim, Soo Hyun Kim, Tae Heon Han, Deok Hyun Lee, Sung Won Development and Validation of the Korean Version of Expanded Prostate Cancer Index Composite: Questionnaire Assessing Health-Related Quality of Life after Prostate Cancer Treatment |
title | Development and Validation of the Korean Version of Expanded Prostate Cancer Index Composite: Questionnaire Assessing Health-Related Quality of Life after Prostate Cancer Treatment |
title_full | Development and Validation of the Korean Version of Expanded Prostate Cancer Index Composite: Questionnaire Assessing Health-Related Quality of Life after Prostate Cancer Treatment |
title_fullStr | Development and Validation of the Korean Version of Expanded Prostate Cancer Index Composite: Questionnaire Assessing Health-Related Quality of Life after Prostate Cancer Treatment |
title_full_unstemmed | Development and Validation of the Korean Version of Expanded Prostate Cancer Index Composite: Questionnaire Assessing Health-Related Quality of Life after Prostate Cancer Treatment |
title_short | Development and Validation of the Korean Version of Expanded Prostate Cancer Index Composite: Questionnaire Assessing Health-Related Quality of Life after Prostate Cancer Treatment |
title_sort | development and validation of the korean version of expanded prostate cancer index composite: questionnaire assessing health-related quality of life after prostate cancer treatment |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941808/ https://www.ncbi.nlm.nih.gov/pubmed/20856644 http://dx.doi.org/10.4111/kju.2010.51.9.601 |
work_keys_str_mv | AT chungkyungjin developmentandvalidationofthekoreanversionofexpandedprostatecancerindexcompositequestionnaireassessinghealthrelatedqualityoflifeafterprostatecancertreatment AT kimjungjun developmentandvalidationofthekoreanversionofexpandedprostatecancerindexcompositequestionnaireassessinghealthrelatedqualityoflifeafterprostatecancertreatment AT limsoohyun developmentandvalidationofthekoreanversionofexpandedprostatecancerindexcompositequestionnaireassessinghealthrelatedqualityoflifeafterprostatecancertreatment AT kimtaeheon developmentandvalidationofthekoreanversionofexpandedprostatecancerindexcompositequestionnaireassessinghealthrelatedqualityoflifeafterprostatecancertreatment AT handeokhyun developmentandvalidationofthekoreanversionofexpandedprostatecancerindexcompositequestionnaireassessinghealthrelatedqualityoflifeafterprostatecancertreatment AT leesungwon developmentandvalidationofthekoreanversionofexpandedprostatecancerindexcompositequestionnaireassessinghealthrelatedqualityoflifeafterprostatecancertreatment |